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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
lymphoid neoplasm. It is an aggressive disease and only 50% of
affected patients can be cured with anthracycline-based CHOP
or CHOP-like chemotherapy. Following the addition of ritux-
imab to CHOP, response rates and survival have improved sig-
nificantly.1-6 Despite these advances, 20-40% of patients treated
with a curative intent experience disease relapses or have pri-
mary refractory disease. 
The International Prognostic Index (IPI) has so far remained
the strongest prognostic factor in DLBCL.7,8 In general, patients
with high IPI scores have a poor prognosis, even if they have
received rituximab-containing therapies.8 Nevertheless, the out-
come of some patients is comparable to that of low-risk patients,
indicating biological diversity within the clinical risk groups.
Gene expression profiling and next-generation sequencing
studies have provided seminal biological information to
explain the clinical behavior of DLBCL and have also led to
the discovery of novel molecular predictors for survival. On
the basis of gene expression profiling, DLBCL can be classi-
fied into distinct molecular subtypes.9-13 Three major DLBCL
entities, showing germinal center B-cell, activated B-cell-like,
and primary mediastinal B-cell lymphoma signatures, have
been identified. Of these, patients with lymphomas with acti-
vated B-cell-like signatures have a shorter survival than
patients with either of the other two molecular subtypes.10 In
addition, studies based on gene expression profiling have
identified the tumor microenvironment and host inflammato-
ry response as defining features in DLBCL.10,13 It is noteworthy
that the “stromal-1” signature, which is associated with good
outcome after chemoimmunotherapy, includes genes that are
typically expressed by components of the extracellular matrix
and monocytes.10
At the cellular level, the immune infiltrate in DLBCL compris-
es macrophages, dendritic cells, mast cells, natural killer cells,
innate immune and lymphoid cells including CD4+ T cells (T-
helper cells), along with cytotoxic T and non-malignant B cells.
Of these, particularly mast cells and tumor-associated
macrophages (TAM) have been discovered to have prognostic
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The prognostic impact of the tumor microenvironment in diffuse large B-cell lymphoma has not been systemati-
cally assessed. We analyzed mRNA and antigen expression of monocytes, macrophages, lymphocytes, dendritic
and natural killer cells in pretreatment tumor samples of patients with high-risk diffuse large B-cell lymphoma
using gene expression microarray and immunohistochemistry. The patients were treated in a Nordic phase II study
with dose-dense chemoimmunotherapy and central nervous system prophylaxis. Of the studied markers for non-
malignant inflammatory cells, CD68 expression and CD68+ macrophage counts correlated with favorable out-
come. Five-year progression-free survival rates were 83% and 43% for the patients with high and low CD68
mRNA levels, respectively (P=0.007), while overall survival rates were 83% and 64%, respectively (P=ns). The
patients with high CD68+ macrophage counts had better 5-year progression-free survival (74% versus 40%;
P=0.003) and overall survival (90% versus 60%; P=0.009) than the patients with low macrophage counts. Low
CD68+ macrophage count retained its prognostic impact on overall survival with age-adjusted International
Prognostic Index [RR=5.0 (95% CI 1.024-19.088); P=0.017]. The findings were validated in three independent
cohorts of patients treated with chemoimmunotherapy. In contrast, in patients treated with chemotherapy, high
CD68+ macrophage count was associated with poor progression-free survival (40% versus 72%; P=0.021) and over-
all survival (39% versus 72%; P=0.015). Together, the data suggest that macrophages exhibit a dual, treatment-spe-
cific role in diffuse large B-cell lymphoma. For the patients treated with chemoimmunotherapy, high pretreatment
CD68 mRNA levels and CD68+ macrophage numbers predict a favorable outcome.
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ABSTRACT
impact in DLBCL.14-17 Of the macrophages, classically acti-
vated M1 type TAM have been described as “good”, acting
to prevent the growth of tumor tissue, whereas the alter-
native M2 type TAM may have an opposite effect pro-
moting angiogenesis and tumor development.18-20
Importantly, however, studies in follicular lymphoma
have demonstrated that the prognostic significance of the
tumor microenvironment and especially macrophages is
highly dependent on a given therapy.21-23
In the present study, we investigated how the combina-
tion of rituximab with chemotherapy influences non-malig-
nant inflammatory cell-associated clinical outcome in
DLBCL. Among all studied markers for macrophages, den-
dritic, and lymphoid cells, we found that pretreatment gene
expression of a macrophage marker CD68 and immunohis-
tochemically defined CD68+ TAM content had a positive
prognostic impact on the survival of DLBCL patients treated
with chemoimmunotherapy, whereas in patients treated
without rituximab, CD68+ TAM content was associated
with a poor outcome.
Methods
Patients and samples
The screening cohort consisted of prospectively collected DLBCL
patients who were less than 65 years old and had primary high-risk
(age-adjusted IPI score 2-3) disease. They were treated in the Nordic
phase II NLG-LBC-04 protocol with dose-dense chemoim-
munotherapy followed by systemic central nervous system pro-
phylaxis.24 The patients in this correlative study represent a subset
of patients in the main clinical trial and were selected on the basis
of DLBCL histology, the availability of fresh frozen tissue for RNA
extraction and exon arrays (gene expression cohort; n=38) and for-
malin-fixed, paraffin-embedded lymphoma tissue containing ade-
quate material for the preparation of tissue microarrays (TMA;
immunohistochemistry cohort; n=59), and the patients’ consent to
correlative studies. Details of the screening cohort are provided in
Table 1, the Online Supplementary Material and Online Supplementary
Table S1. 
The clinical protocol and sampling were approved by
Institutional Review Boards, National Medical Agencies and Ethics
Committees in Denmark, Finland, Norway and Sweden, and the
trial was registered at ClinicalTrials.gov, number NCT01502982.
To validate the findings, three independent retrospective series
of chemoimmunotherapy-treated DLBCL patients were used. In
order to confirm gene expression data, we used RNA sequencing
data from 92 patients generated by the Cancer Genome
Characterization Initiative (CGCI; dbGaP database applied study
accession: phs000532.v3.p1)25,26 and oligonucleotide-based
microarray data from 233 DLBCL patients generated by the
Lymphoma/Leukemia Molecular Profiling Project (LLMPP; GEO
dataset: GSE10846).10 Both cohorts are subsets of the original
study populations treated with a R-CHOP-like regimen based on
the availability of complete expression data and clinical informa-
tion (Online Supplementary Table S2). 
In order to confirm the immunohistochemical data, an independ-
ent population-based series of 72 primary DLBCL patients treated
with chemoimmunotherapy at the Helsinki University Central
Hospital between 2001 and 2006 was used (Table 2). In addition, 50
DLBCL patients treated with chemotherapy in Helsinki before rit-
uximab was adopted into clinical routine, and the LLMPP pre-ritux-
imab cohort  (n=181) treated with CHOP10 served as pre-rituximab
control groups. Details of the validation cohorts are provided in the
Online Supplementary Material.
Gene expression
Gene expression levels of CD68, CD163, and C-C motif chemokine
ligand 18 (CCL18)were determined from the exon array-based data
set of 38 pre-treatment lymphoma samples (Affymetrix Human
Exon 1.0 ST arrays) from the patients treated in the Nordic phase II
NLG-LBC-04 protocol,27 and from the data set of ten pairs of lym-
phoma samples collected before and a day after the first course of
R-CHOP. Hybridization protocols and raw expression microarray
data are available at the ArrayExpress archive
(http://www.ebi.ac.uk/microarray-as/ae/ID: E-MEXP-3488 and ID: E-
MTAB-2471).
Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed
paraffin-embedded tissue sections on TMA slides or whole tissue
sections (independent validation cohorts) with antibodies against
CD68, CD163, CCL18, CD3, CD4, CD8, CD14, CD21, CD57 and
GCET1 according to the manufacturer's instructions. Detailed
information on the antibodies and scoring of the staining are
described in the Online Supplementary Material. 
Statistical analyses
Data were analyzed using PASW Statistics 18.0 (SPSS, Inc.) and
are described in detail in the Online Supplementary Material.
Probability values below 0.05 are considered statistically significant
and all P values are two-tailed.
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Table 1. Baseline characteristics and outcome of the original study
population, and exon array and TMA cohorts from the Nordic phase II
study.
Characteristic Clinical Gene Immunohistochemistry 
trial1 expression (TMA)
(exon array)
Number of patients 143 38 59
Median age (range) 54 53 53
(18-65) (20-64) (18-65)
Age
<60 years 104 (73) 29 (76) 44 (75)
≥60 years 39 (27) 9 (24) 15 (25)
Gender
Male 92 (64) 24 (63) 41 (69)
Female 51 (36) 14 (37) 18 (31)
Age-adjusted IPI
2 104 (73) 27 (71) 42 (71)
3 39 (27) 11 (29) 17 (29)
DLBCL molecular 
subgroup
GCB 72 (50) 24 (63) 32 (54)
Non-GCB 32 (22) 9 (24) 21 (36)
PMBL 7 (5) 2 (5) 3 (5)
Unknown 32 (22) 3 (8) 3 (5)
Relapses 43 10 16
Deaths 34 9 11
Lymphoma-specific 25 5 9
Other 9 4 3
5-year PFS 70% 72% 74%
5-year OS 78% 76% 84%
1Cases with follicular lymphomas have been excluded; GCB: germinal center B-cell
like; PMBL: primary mediastinal B-cell lymphoma; PFS: progression-free survival; OS:
overall survival.
Results
Characteristics of the patients and diseases
The clinical characteristics of the prospective cohorts of
patients who received treatment in the Nordic phase II
study24 are listed in Table 1. There were no major differ-
ences in the baseline characteristics or outcomes between
the cases originally included in the trial and the cases
available for the correlative studies, implying that the
cases were representative of the entire clinical trial. The
median follow up was 65 months for both the gene
expression and TMA cohorts. In the gene expression
cohort (n=38), nine patients had relapsed and nine died.
Two of the deaths were not lymphoma-related, including
one toxic death and one suicide. Five-year progression-
free survival (PFS) and overall survival (OS) rates were
72% and 76%, respectively. In the TMA cohort (n=59),
there were 16 relapses and 11 deaths. One of the deaths
was due to secondary cancer. Five-year PFS and OS rates
were 72% and 85%, respectively.
Gene expression data
We utilized the exon array database27 to address whether
there was a correlation between survival and gene expres-
sion of CD68, CD163, and CCL18 in the lymphoma tissue.
Of these CD68 encodes a pan-macrophage marker
expressed on both classically activated M1 type and alter-
native M2 type macrophages, whereas CD163 expression
is more specific for the latter subtype. Likewise, CCL18
expression has been recognized as a marker for M2 type
macrophages.28 The baseline characteristics of the array
cohort are shown in Table 1. CD68 gene expression was
found to correlate with CD163 (rs=0.574, P<0.001) and
CCL18 (rs=0.426, P=0.008) mRNA levels. When the associ-
ation between gene expression and survival was analyzed,
high CD68 mRNA levels were found to have a favorable
impact on PFS (P=0.016) although not on OS (P=ns), and no
associations were found between CD163 or CCL18
expression and survival parameters. According to Kaplan-
Meier analysis using an optimal cutoff level of 37%,29 the
5-year PFS rate for the patients with high CD68mRNA lev-
els was 83% as compared with 43% for the patients with
low CD68 expression (P=0.009; Figure 1A). The correspon-
ding 5-year OS rates were 83% and 63% (P=ns; Figure 1B).
When clinical characteristics of the patients were com-
pared according to CD68 expression, no significant differ-
ences in age, gender, age-adjusted aIPI scores, or molecular
subtype were observed between the subgroups (Online
Supplementary Table S1). 
In order to find support for our CD68 expression data,
we analyzed the prognostic significance of CD68 gene
expression in the CGCI25,26 and LLMPP10 data sets. The char-
acteristics of the patients in these cohorts and their diseases
are described in the Online Supplementary Material (Online
Supplementary Table S2). In the CGCI cohort, high CD68
gene expression predicted favorable OS (P=0.033). When
the optimal cutoff level of 35% was used to discriminate
the outcomes between the low and high CD68 subgroups,
the 3-year OS rate of the patients with high CD68 mRNA
levels was 86% compared with 67% for those with low
levels (P=0.040; Figure 1C). When the originally defined
cutoff level was used (37%), the difference between the
low and high CD68 subgroups was of borderline signifi-
cance (P=0.071). In the LLMPP data set with the optimal
cutoff level of 23%, 5-year OS rates were 72% and 58%
for the patients with high and low CD68 mRNA levels,
respectively (P=ns; Figure ID).
Association of CD68+ tumor-associated macrophage 
content with survival
Next, we analyzed the prognostic impact of CD68+ TAM
content on survival in the Nordic phase II study population.
Tumor tissue for TMA analysis and immunohistochemistry
was available for 59 patients (Table 1). Number of CD68+
TAM correlated with CD68 gene expression (rs=0.584,
P=0.009) and CD163+ TAM counts (rs=0.780, P=0.001).
Likewise, CD163+ TAM counts correlated with CD163
(rs=0.857, P<0.001) and CD68 (rs=0.597, P=0.005) gene
expression. Furthermore, there was a good concordance for
CD68+ TAM analyses performed in two laboratories
(rs=0.770, P<0.001).
The median level of CD68+ TAM/high power field (hpf)
was 37 (range, 5-95). The cutoff level of 26 TAM/hpf, corre-
sponding to 17%, was found to discriminate best between
subgroups with different outcomes. According to Kaplan-
Meier estimates, the patients with high CD68+ TAM counts
had a 5-year PFS of 74% in comparison to 40% for those
with lower CD68+ TAM counts (P=0.003; Figure 2A), and a
better 5-year OS (90% versus 60%, P=0.009; Figure 2B). In
multivariate analysis with age-adjusted IPI, low CD68+ TAM
count retained its adverse prognostic value on OS [CD68+
TAM, RR=5.037 (95% CI 1.329-19.088), P=0.017; IPI,
RR=3.981 (95% CI 1.024-14.578), P=0.046]. No differences
were observed in stage, IPI scores or molecular subgroups
S. Riihijärvi, et al.
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Table 2. Baseline characteristics according to CD68+ TAM content in
the chemoimmunotherapy validation cohort.
Characteristic CD68+ TAM
All Low High P
Number of patients 72 55 17
Median age 64 65 63
(range) (20-80) (20-80) (42-77)
Age
<60 years 28 (39) 21 (38) 7 (41) 1.000
≥60 years 44 (61) 34 (62) 10 (59)
Gender
Male 41 (57) 29 (53) 12 (71)
Female 31 (43) 26 (47) 5 (29) 0.265
Stage
I-II   34 (47) 26(47) 8 (47)
III-IV 37 (52) 28 (51) 9 (53) 1.000
Missing 1 (1) 1 (2)
IPI score
0-2 49 (68) 38 (69) 11 (65)
3-5 23 (32) 17 (31) 6 (35) 0.771
Molecular subgroup
GCB 18 14 (25) 4 (24)
Non-GCB 27 22 (40) 5 (29) 1.000
Missing 27 19 (35) 8 (47)
Relapses 18 17 1 0.031
Deaths
Lymphoma-specific 20 18 2 0.125
Other 14 13 1
6 5 1
GCB: germinal center B-cell like.
between the low and high CD68+ TAM groups (Online
Supplementary Table S1).
To determine the prognostic impact of other cells in the
reactive microenvironment on survival, mRNA levels of the
pan T-lymphocyte marker CD3 (chains e, d and g), T-helper
cell antigen CD4, cytotoxic T-cell antigen CD8 (chains a and
b), monocyte antigen CD14, follicular dendritic cell marker
CD21 and natural killer-cell marker CD57, as well as germi-
nal center B-cell marker GCET1 were analyzed.
Furthermore, the samples were immunostained and quanti-
fied for CD163, CCL18, CD3, CD4, CD8, CD14, CD21,
CD57 and GCET1 positivity. For all markers, the gene
expression levels correlated with the corresponding cell
counts, and CD14+ cell counts correlated with CD68+ TAM.
However, neither gene expression levels nor any of the cell
counts were associated with survival.
Association of tumor-associated macrophages 
with survival in an independent series of patients 
with diffuse large B-cell lymphoma
To validate the positive prognostic value of high CD68+
TAM content in the rituximab era, we used an independent
population-based set of 72 DLBCL patients treated with
chemoimmunotherapy. The baseline characteristics of the
validation cohort are listed in Table 2. Instead of a TMA-
based analyses, immunohistochemical staining was per-
formed on individual whole tissue sections. The relations
between CD68+ TAM and baseline characteristics are
shown in Table 2. In this cohort, the median level for CD68+
TAM/hpf was 33 (range, 13-67). The cutoff level of 43
CD68+ TAM/hpf corresponding to 76% was found to dis-
criminate best between subgroups with different outcomes.
When this cutoff level was used, no differences were
observed in age, stage, IPI scores or molecular subgroups
between patients in the low and high CD68+ TAM groups. 
The clinical outcomes according to treatment and CD68+
TAM content in the validation cohort are shown in Figure 3.
According to Kaplan Meier analysis, 5-year PFS rates were
88% and 65% for the patients with high and low numbers
of CD68+ TAM, respectively (P=0.050; Figure 3A). The cor-
responding OS rates were 88% and 72%, respectively
(P=ns; Figure 3B). The risk of relapse was 3.7-fold higher for
the patients with low CD68+ TAM counts (95% CI 0.903-
16.462, P=0.068) and 2.5-fold higher for the patients with
high IPI scores (CI 95% 1.104-5.492, P=0.028). In multivari-
ate analyses with IPI, the negative prognostic impact of low
TAM content on PFS was of borderline significance (RR 4.1,
95% CI 0.948-17.309, P=0.059; for IPI, RR 2.6, 95% CI
1.149-5.722, P=0.021). 
Response of tumor-associated macrophages to treatment 
To evaluate the impact of therapy on TAM, we analyzed
the expression of macrophage markers and the number of
TAM from ten DLBCL pairs of samples collected before the
treatment and 1 day after the first chemoimmunotherapy
infusion had ended. Comparison of pre- and post-treatment
tissue samples in this small cohort of patients showed an
increase in mRNA levels of CD68 (P=0.052), CD163
(P=0.023) and CCL18 (P=0.042) genes in response to therapy
(Figure 4A). Consistent with the gene expression data, a sig-
nificant increase in the number of CD68+ TAM (53 versus 68,
P=0.023) (Figure 4B), and a non-significant increase in the
Tumor-associated macrophages in DLBCL
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Figure 1. Survival accord-
ing to CD68 gene expres-
sion in different
chemoimmunotherapy
cohorts. PFS (A) and OS
(B) rates according to low
and high CD68 gene
expression in the Nordic
phase II exon array
cohort. (C) OS according
to CD68 gene expression
in the CGCI cohort. (D) OS
according to CD68 gene
expression in the LLMPP
cohort. 
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CD163+ TAM counts (67 versus 77) was also observed. CD3
(CD3e, P=0.003; CD3d, P=0.010; CD3g P=0.013), CD4
(P=0.021), and CD8 (CD8a, P=0.009) mRNA levels also
increased in response to therapy, while CD20 and CD21 lev-
els did not show significant changes. 
Association of tumor-associated macrophages 
with survival in the pre-rituximab era
Finally, we evaluated the prognostic impact of TAM on
the outcome of 50 DLBCL patients who received therapy
before rituximab was routinely available (pre-rituximab era).
The characteristics of the patients in this pre-rituximab
cohort are shown in Online Supplementary Table S3. Thirty
patients received high-dose therapy and autologous stem
cell transplantation as consolidation after their first-line ther-
apy, and 20 as salvage therapy for relapsed disease. The
median number of CD68+ TAM/hpf was 58 (range, 19-83).
No differences were observed in baseline characteristics
between patients in the high and low CD68+ TAM sub-
groups (Online Supplementary Table S3).
According to Kaplan-Meier estimates (Online
Supplementary Figure S1), the patients with low CD68+ TAM
content had better 5-year PFS and OS rates when compared
to patients with high CD68+ TAM counts (72% versus 40%,
P=0.021 for PFS and 72% versus 39%, P=0.015 for OS).
When the patients were divided into two groups according
to the time of autologous transplantation, the patients treat-
ed with high-dose therapy as salvage therapy and with low
CD68+ TAM counts at diagnosis had significantly better OS
than the ones with high counts (70% versus 13%, P=0.020).
A non-significant difference was also observed in the
patients who received the treatment frontline (80% versus
47%, P=0.083). The results confirm previous findings in
chemotherapy-treated patients.15,16 
To complement the data on CD68+ TAM, we analyzed
CD68 gene expression in relation to OS from the LLMPP
CHOP cohort.  With the cutoff level of 19%, 5-year OS rates
were 45% and 55% for the patients with high and low
CD68 mRNA levels (P=ns; Online Supplementary Figure S2).
Together, the data suggest that addition of rituximab to
chemotherapy reverses the negative prognostic impact of
high CD68+ TAM content to favorable.
Discussion
Our aim was to determine how the combination of ritux-
imab with chemotherapy influences tumor infiltrating
inflammatory cell-associated survival in DLBCL. The results
from a prospectively collected screening cohort of patients
treated homogenously in the Nordic phase II study showed
that high CD68 gene expression and high number of CD68+
TAM were associated with favorable PFS and OS in DLBCL
patients treated with chemoimmunotherapy. Furthermore,
S. Riihijärvi, et al.
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Figure 2. PFS (A) and OS (B) according to high and low CD68+ TAM in
the Nordic phase II TMA cohort.
Figure 3. PFS (A) and OS (B) according to CD68+ TAM in the chemoim-
munotherapy validation cohort.
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CD68+ TAM content was identified as an independent risk
factor for OS.  In comparison, no correlation between
CD163, CCL18, CD14, CD21, CD3, CD4, CD8 and CD57
expression or corresponding antigen-positive cells and out-
come was found. The results on CD68 expression and
CD68+ TAM counts were validated in three larger independ-
ent cohorts. In addition, we demonstrated an inflammatory
response including an increased TAM content in response to
chemoimmunotherapy.
Macrophages are divided into at least M1 and M2 sub-
types, which express different levels of cell surface markers,
adhesion molecules, scavenger receptors, chemokines,
cytokines, and receptors, and show different effector func-
tions.19,20 Studies on solid tumors have shown that TAM dis-
play a M2 type phenotype,30,31 and that TAM content often
correlates with poor survival. We observed that in DLBCL
patients treated with chemotherapy alone, high CD68+
TAM content was associated with a poor prognosis.
However, in the case of lymphomas treated with a ritux-
imab-containing regimen, the effect of CD68+ macrophages
in the lymphoma tissue was opposite. The data allow the
speculation that TAM can switch from a tumor-promoting
to a tumor-inhibiting function in response to rituximab. 
Our analyses showed a correlation of CD68mRNA lev-
els and immunohistochemically defined CD68+ TAM
counts with survival, whereas no association between the
expression of M2 type macrophage markers CD163 or
CCL18 and survival was found. Of these antigens CD163
is a hemoglobin scavenger receptor playing a major role in
dampening the inflammatory response and in scavenging
components of damaged cells.32 CCL18 expression is
known to contribute to the active recruitment of lympho-
cytes and immature dendritic cells under inflammatory
and pathological conditions.28 Interestingly, CCL18 has
also been shown to be able to stimulate monocytes to
mature into macrophages.33 Although the terms M1 and
M2 macrophages are simplifications of reality, they have
been used to explain the opposing functions of different
macrophage subsets. A large proportion of M1 type TAM
in the total macrophage content may provide better
tumor control, since the overall balance in the tumor
microenvironment shifts to the anti-tumor response. If
M2 type macrophages predominate, the balance may,
instead, shift to a pro-tumor microenvironment. Our find-
ings in the chemoimmunotherapy-treated patients may,
therefore, reflect the anti-tumor effects of M1 type TAM
dominating over the pro-tumor effect of the M2 type
TAM, whereas in the chemotherapy-treated cohort the
effect is opposite.
In our patients, both CD68 mRNA levels and CD68+
TAM content predicted outcome.  Similar results were also
recently reported at the protein level by others.17 The find-
ings at multiple levels are important because the optimal
cutoff levels best discriminating the low and high sub-
groups varied between different cohorts. Several explana-
tions for this variability are possible. It is likely that true
microenvironment-related differences exist between differ-
ent populations of patients. However, it is also conceivable
that methodological differences, especially in specimen
preparation (TMA versuswhole sections), and intratumoral
heterogeneity influence scoring results. Furthermore, we
recognize the limitations of small cohorts of patients.
Thus, data from different series should be compared with
special caution. It is also important to emphasize that we
do not consider certain cutoff points to be biologically sig-
nificant, but rather think that CD68 expression and CD68+
TAM levels form a continuum with increased numbers of
TAM correlating with improved survival in patients treated
with chemoimmunotherapy.
At present it remains unclear how TAM could switch
from a tumor-promoting to tumor-suppressing function
when rituximab is combined with chemotherapy.
Nevertheless, macrophages have been implicated as crucial
players in the mechanisms of actions of CD20 antibodies
including rituximab.34-36 They mediate antibody-dependent
cellular phagocytosis, and are also involved in antibody-
dependent cellular cytotoxicity. Interestingly, preclinical
data demonstrate that M2 type macrophages phagocytose
rituximab-opsonized lymphoma cells more efficiently than
do M1 type cells.37 Our findings that macrophage markers
and content increase in tumor tissue in response to a ritux-
imab-containing regimen enable speculation that a favor-
able outcome could be a consequence of more efficient
macrophage-mediated phagocytosis of lymphoma cells.
Macrophages may also secrete cytolytic factors or release
cytokines, thereby recruiting other effector cells to amplify
the inflammatory response. Conversely, lymphoma cells
can secrete cytokines, including interleukin-10, which
favor alternative activation of macrophages to M2 type
cells. Considering that tissue macrophages are critical for B-
cell depletion after anti-CD20 therapy,34,35,38 it is possible
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Figure 4. (A) Expression of CD68 mRNA before and after the first R-
CHOP course. (B) Number of CD68+ TAM before and after the first R-
CHOP course.  
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that there is an interrelationship between TAM content
and efficacy of rituximab. Together the data support a
hypothesis that macrophages mediate the therapeutic
activity of rituximab treatment.36,38-40
An additional aim of this study was to explore the effect
of chemoimmunotherapy on the tumor microenvironment.
The analysis has limitations due to the small number of
evaluable patients and lack of control group treated without
rituximab; however, when pre-treatment and 1-day post-
treatment samples were compared, an increase in gene
expression of macrophage markers and TAM in response to
chemoimmunotherapy was found. This observation is in
line with in vitro findings showing the immune-stimulatory
effect of rituximab on macrophages.37 Alternatively, the find-
ing may reflect an association of increased numbers of
macrophages with a tissue repair process during chemother-
apy-induced cell death. A more detailed comparison of the
composition of the tumor microenvironment at diagnosis,
during treatment and at relapse will be instrumental in iden-
tifying the cellular niche which is either promoting drug-
induced lymphoma cell death or alternatively protecting
lymphoma cells from cytotoxicity.
Macrophage-mediated lymphoma depletion during
chemoimmunotherapy may have clinical implications. For
example, it may be possible to stimulate macrophage activ-
ity further in the tumor tissue with the use of granulocyte-
macrophage  or macrophage colony-stimulating factors
(GM-CSF or M-CSF).37,39 Administration of GM-CSF or M-
CSF activates numerous immune cells, notably granulocytes
and monocytes, which express FCγ receptors and are
involved in rituximab-mediated antibody-dependent cellular
cytotoxicity and phagocytosis.39,41 Furthermore, GM-CSF can
upregulate CD20 expression on lymphoma cells.42 The con-
cept of GM-CSF-induced immune priming has been success-
fully used in combination with rituximab monotherapy in
patients with relapsed or progressive follicular lymphoma,43
and recently also tested with R-CHOP in patients with pri-
mary DLBCL.44,45 Another novel and promising immunother-
apeutic approach is to augment rituximab-mediated anti-
body-dependent cellular phagocytosis by combining ritux-
imab with another antibody or a peptide, which inhibits the
CD47-mediated antiphagocytic signaling pathway that the
cancer cells use to inhibit macrophage-mediated
destruction.40,46
Unlike CD68+ TAM, the rest of the cells present in the
reactive microenvironment had no impact on survival. Our
results for the T-cell markers CD3 and CD4 differ from
those in a recently published study, in which high levels of
CD3+ and CD4+ T cells were associated with favorable prog-
nosis.47 Due to major differences in the study populations,
treatments and methodologies used for cell quantification
(immunohistochemistry versus flow cytometry), the results
from these studies are not comparable.
In conclusion, we have shown that TAM exhibit a dual
treatment-dependent role in the pathogenesis of DLBCL.
While high TAM counts are associated with poor outcome
in patients treated with chemotherapy, this adverse prog-
nostic impact is inversed when rituximab is combined with
chemotherapy. Similar functional plasticity of TAM has pre-
viously been shown to occur in follicular lymphoma.21,23 The
strengths of our study are a prospectively collected and
homogenously treated study population, the availability of
gene expression and immunohistochemical data from the
same cohort of patients, and the possibility of validating the
results in three independent cohorts of DLBCL patients. The
limitations of the study include relatively small sample sizes,
disparate study populations and different specimen prepara-
tion (TMA versus whole sections). Furthermore, we recog-
nize that the TMA design does not optimally reflect the
entire distribution of tumor infiltrating inflammatory cells
because of regional variation in their localization.
Nevertheless, our findings establish a macrophage marker,
CD68, to be important in predicting the survival of patients
with DLBCL and warrant its evaluation in prospective, clin-
ical trials of DLBCL.
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